Cargando…

Reactions to learning a “not elevated” amyloid PET result in a preclinical Alzheimer’s disease trial

BACKGROUND: The experiences of biomarker-ineligible cognitively normal persons can inform trial conduct and the translation of preclinical Alzheimer’s disease (AD) into clinical practice. METHODS: We interviewed 33 persons whose “not elevated” brain amyloid imaging biomarker result made them ineligi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grill, Joshua D., Cox, Chelsea G., Harkins, Kristin, Karlawish, Jason
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303934/ https://www.ncbi.nlm.nih.gov/pubmed/30579361 http://dx.doi.org/10.1186/s13195-018-0452-1

Ejemplares similares

Response to “Avoiding Methodological Bias in Studies of Amyloid Imaging Results Disclosure”
por: Grill, Joshua D., et al.
Publicado: (2019)

Cognitively unimpaired adults’ reactions to disclosure of amyloid PET scan results
por: Largent, Emily A., et al.
Publicado: (2020)

Study partners should be required in preclinical Alzheimer’s disease trials
por: Grill, Joshua D., et al.
Publicado: (2017)

Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants
por: Harkins, Kristin, et al.
Publicado: (2015)

African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials
por: Zhou, Yan, et al.
Publicado: (2016)

How Biomarker-Based Diagnosis and Treatment Affect Alzheimer’s Stigma: Results of a Randomized Trial
por: Stites, Shana, et al.
Publicado: (2021)

Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials
por: Grill, Joshua D, et al.
Publicado: (2010)

‘That would be dreadful’: The ethical, legal, and social challenges of sharing your Alzheimer’s disease biomarker and genetic testing results with others
por: Largent, Emily A, et al.
Publicado: (2021)

Study partners: essential collaborators in discovering treatments for Alzheimer’s disease
por: Largent, Emily A., et al.
Publicado: (2018)

Preclinical Alzheimer Disease and the Electronic Health Record: Balancing Confidentiality and Care
por: Gale, Seth A., et al.
Publicado: (2022)

Effects of Self-Identification as a Caregiver on Expectations of Public Stigma of Alzheimer’s Disease
por: Stites, Shana D., et al.
Publicado: (2021)

Asymmetric amyloid deposition in preclinical Alzheimer’s disease: A PET study
por: Kjeldsen, Pernille L., et al.
Publicado: (2022)

Recruiting to preclinical Alzheimer's disease clinical trials through registries
por: Grill, Joshua D.
Publicado: (2017)

Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer’s trials
por: Nuño, Michelle M., et al.
Publicado: (2019)

Communicating mild cognitive impairment diagnoses with and without amyloid imaging
por: Grill, Joshua D., et al.
Publicado: (2017)

Amyloid duration is associated with preclinical cognitive decline and tau PET
por: Koscik, Rebecca L., et al.
Publicado: (2020)

Gender Differences in How the American Public Reacts to a Person With Mild-Stage Dementia
por: Stites, Shana, et al.
Publicado: (2020)

Synthesis, characterization, and preclinical validation of a PET radiopharmaceutical for interrogating Aβ (β-amyloid) plaques in Alzheimer’s disease
por: Sundaram, Guruswami SM, et al.
Publicado: (2015)

Preclinical and clinical study on [(18)F]DRKXH1: a novel β-amyloid PET tracer for Alzheimer’s disease
por: Xu, MiaoMiao, et al.
Publicado: (2021)

Anticipated reactions to learning Alzheimer’s disease biomarker results
por: Clark, Lindsay R., et al.
Publicado: (2022)

The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer’s disease
por: Hahn, Alice, et al.
Publicado: (2020)

Advances in Alzheimer's imaging are changing the experience of Alzheimer's disease
por: Stites, Shana D., et al.
Publicado: (2018)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2020)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2021)

What is paradoxical lucidity? The answer begins with its definition
por: Peterson, Andrew, et al.
Publicado: (2021)

IS THERE A DIFFERENCE BETWEEN TERMINAL LUCIDITY AND PARADOXICAL LUCIDITY?
por: Peterson, Andrew, et al.
Publicado: (2022)

Amyloid PET imaging: applications beyond Alzheimer’s disease
por: Catafau, Ana M., et al.
Publicado: (2015)

Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease
por: Wang, Jun, et al.
Publicado: (2011)

Cognitive Decline in Preclinical Alzheimer’s Disease: Amyloid-Beta versus Tauopathy
por: Huber, Colin M., et al.
Publicado: (2017)

Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease
por: Pascoal, Tharick A., et al.
Publicado: (2018)

Brain amyloid in preclinical Alzheimer's disease is associated with increased driving risk
por: Ott, Brian R., et al.
Publicado: (2016)

Self-Supervised Contrastive Learning to Predict Alzheimer’s Disease Progression with 3D Amyloid-PET
por: Kwak, Min Gu, et al.
Publicado: (2023)

Self-Supervised Contrastive Learning to Predict the Progression of Alzheimer’s Disease with 3D Amyloid-PET
por: Kwak, Min Gu, et al.
Publicado: (2023)

PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer’s disease-causing Presenilin-1 E280A mutation carriers
por: Ghisays, Valentina, et al.
Publicado: (2021)

Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial
por: Raman, Rema, et al.
Publicado: (2021)

Topographical Heterogeneity of Alzheimer’s Disease Based on MR Imaging, Tau PET, and Amyloid PET
por: Jeon, Seun, et al.
Publicado: (2019)

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
por: Alcolea, Daniel, et al.
Publicado: (2019)

Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease()
por: Chételat, Gaël, et al.
Publicado: (2013)

Beta-amyloid and Cortical Thickness Reveal Racial Disparities in Preclinical Alzheimer's Disease
por: McDonough, Ian M.
Publicado: (2017)

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i11l1htm806s49v85mitvrq256